← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Costello Syndrome

MONDO:0009026 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 15 citations asta · 20 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Costello syndrome is caused by heterozygous germline gain-of-function variants in the proto-oncogene HRAS, placing it among the RASopathies.

UNANIMOUS INTEGRATED
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Costello syndrome (CS) is a Rasopathy caused by heterozygous, germline gain-of-function variants in HRAS that dysregulate Ras protein signal transduction and downstream effector pathways.
Falcon names germline gain-of-function HRAS as the RASopathy cause directly.
asta CONCORDANT 90% Costello syndrome (CS, OMIM #218040) is caused by heterozygous germline mutations in the proto-oncogene HRAS that cause dysfunction of the Ras-MAPK signaling pathway.
A retrieved Asta paper states the same HRAS germline cause and adds the OMIM identifier.
PMID:26812928

The core dysregulated pathway is the canonical RAS/MAPK (Ras-Raf-MEK-ERK) signaling cascade, constitutively activated by mutant HRAS.

UNANIMOUS INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 92% Core signaling derangements include persistent activation of the RAS/MAPK cascade and aberrant PI3K signaling observed in patient-derived cells
Falcon identifies persistent RAS/MAPK activation as the central derangement.
asta CONCORDANT 85% RASopathies, a group of syndromic disorders caused by germline mutations in genes that affect the canonical Ras/MAPK signaling pathway, include Noonan syndrome (NS), NS with multiple lentigines (NSML), Costello syndrome (CS), cardiofaciocutaneous syndrome (CFCS), neurofibromatosis type 1 (NF1), and other clinically related diseases
A retrieved Asta review frames Costello syndrome within the RAS/MAPK RASopathy family.
PMID:35426371

Aberrant/prolonged PI3K-AKT signaling is a second effector axis dysregulated in Costello syndrome, reported in patient fibroblasts.

SINGLE LEAD
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Prolonged PI3K signaling has been reported in HRAS patient fibroblasts, supporting a role for PI3K/AKT axis dysregulation in CS pathogenesis
Falcon documents prolonged PI3K/AKT activity as a distinct effector axis.
asta SILENT —
Asta's retrieved snippets do not address PI3K/AKT signaling in Costello syndrome specifically.

Mutant HRAS inhibits AMPK signaling and impairs mitochondrial proteostasis and oxidative phosphorylation, implicating a bioenergetic defect in Costello syndrome pathophysiology.

SINGLE LEAD
pathophysiology
ProviderStanceScoreEvidence
asta CONCORDANT 90% The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics.
A retrieved Asta paper (Dard et al. 2022) establishes the AMPK/mitochondrial bioenergetic mechanism.
PMID:35230976, DOI:10.1172/JCI131053
falcon SILENT —
Falcon's report does not mention mitochondrial dysfunction or AMPK; it frames pathophysiology around RAS/MAPK, PI3K, and cardiac ion handling.

Cardiovascular disease — hypertrophic cardiomyopathy and supraventricular arrhythmias — is a major feature of Costello syndrome.

MAJORITY INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% CHD around 44%; hypertrophic cardiomyopathy approximately 60–61%; supraventricular arrhythmias in roughly half
Falcon quantifies the cardiac burden in Costello syndrome (CHD, HCM, supraventricular arrhythmia).
DOI:10.3390/genes15081015
asta PARTIAL 50% Cardiac involvement is a major feature of RASopathies, a group of phenotypically overlapping syndromes caused by germline mutations in genes encoding components of the RAS/MAPK (mitogen-activated protein kinase) signaling pathway.
A retrieved Asta review affirms cardiac involvement as a major RASopathy feature but its prevalence figures are Noonan-syndrome-specific, not Costello.
PMID:39202376

HRAS-mutant hiPSC-derived atrial-like cardiomyocytes adopt an enhanced pacemaker/nodal automaticity program, providing a mechanistic model for the multifocal atrial tachycardia seen in Costello syndrome.

SINGLE INTEGRATED
pathophysiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 92% CS-associated gain-of-function HRASG12 mutations in induced pluripotent stem cells-derived [atrial-like cardiomyocytes] trigger transcriptional changes associated with enhanced automaticity and arrhythmic activity consistent with multifocal atrial tachycardia.
Falcon reports the hiPSC atrial cardiomyocyte model linking HRAS to MAT via enhanced automaticity, and nominates ivabradine/flecainide/verapamil as candidate modulators.
DOI:10.1161/circep.123.012022
asta SILENT —
Asta did not retrieve the hiPSC atrial-cardiomyocyte / multifocal atrial tachycardia mechanism.

Costello syndrome carries a characteristic predisposition to malignancy, with an estimated ~10-15% lifetime risk of embryonal rhabdomyosarcoma, neuroblastoma, and transitional cell carcinoma of the bladder.

MAJORITY INTEGRATED
phenotypeprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Tumor predisposition is characteristic, with a lifetime risk on the order of 10–15% for embryonal rhabdomyosarcoma, neuroblastoma, and transitional cell carcinoma of the bladder
Falcon gives the tumor risk estimate and the specific tumor spectrum.
asta PARTIAL 40% predisposition to malignancies
A retrieved Asta paper lists malignancy predisposition among Costello clinical features but gives no risk estimate or tumor spectrum.
PMID:26812928

Pharmacological activation of mitochondrial bioenergetics and quality control rescued disease phenotypes in Costello syndrome models, nominating mitochondrial modulators as a candidate therapeutic strategy.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
asta CONCORDANT 85% Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model.
A retrieved Asta paper reports phenotype rescue by mitochondrial modulators across cell, mouse, and zebrafish CS models.
PMID:35230976
falcon SILENT —
Falcon's treatment discussion centers on MEK inhibition (trametinib) and antiarrhythmics, not mitochondrial modulators.

Costello syndrome is a very rare disorder, with an estimated birth prevalence on the order of 1 in 300,000 to 1 in 1,230,000.

SINGLE LEAD
epidemiology
ProviderStanceScoreEvidence
asta CONCORDANT 80% The birth prevalence of this disease is estimated at 1:1,230,000 to 1:300,000
A retrieved Asta paper provides an explicit birth-prevalence estimate.
PMID:26812928
falcon SILENT —
Falcon reports tumor and cardiac prevalence statistics but no population birth prevalence for the syndrome.

Narrative

Overview

The two providers frame Costello syndrome from opposite ends of the deep-research spectrum. Falcon (Edison Scientific) delivers a synthesized, mechanism-first report that treats Costello syndrome as a prototypic RASopathy: a germline gain-of-function HRAS disorder whose RAS/MAPK (and secondary PI3K) hyperactivation drives multisystem disease, with unusually deep coverage of the cardiac phenotype, an hiPSC atrial-cardiomyocyte model of multifocal atrial tachycardia, and tumor predisposition. Asta is a retrieval-only corpus search whose 20 hits are largely off-topic (subarachnoid hemorrhage, caprine pregnancy toxemia, HHH syndrome, renal ciliopathies, diabetes mitochondria); only a handful of returned papers are genuinely on-topic (Dard 2022, Kontaridis 2022, Faienza 2024, Blachowska 2016). Consequently the harmonized picture is anchored by Falcon, with Asta supplying corroboration for a few shared claims plus a distinct bioenergetic angle and a prevalence figure.

Agreement

Both providers converge on the fundamentals: Costello syndrome is caused by heterozygous germline gain-of-function variants in the proto-oncogene HRAS, and the core dysregulated pathway is the canonical RAS/MAPK cascade. Both also place the disorder explicitly within the RASopathy family and affirm that cardiovascular disease is a major clinical feature. No direct contradictions were found between the reports; every point of contact is concordant or a weaker/qualified (partial) version of the same claim.

Divergence

Divergence is complementary coverage rather than conflict. Falcon uniquely contributes the PI3K/AKT effector axis, the hiPSC atrial-like cardiomyocyte mechanism linking HRAS to multifocal atrial tachycardia via enhanced pacemaker/ nodal automaticity (with ivabradine/flecainide/verapamil as candidate modulators), quantified cardiac burden (CHD, HCM, supraventricular arrhythmia), and the ~10-15% tumor-risk spectrum (rhabdomyosarcoma, neuroblastoma, bladder transitional cell carcinoma). Asta uniquely surfaces the AMPK/mitochondrial bioenergetic mechanism from Dard 2022 — mutant HRAS inhibiting AMPK and impairing mitochondrial proteostasis/oxidative phosphorylation — together with mitochondrial modulators as a candidate therapy and an explicit birth-prevalence estimate. Where Asta touches Falcon's cardiac and tumor claims, its support is only partial: its cardiac prevalence figures are Noonan-syndrome-specific, and its tumor mention is a bare "predisposition to malignancies" with no risk estimate or spectrum.

Integration

The well-supported, provider-concordant claims should be promoted into the disorder YAML: the HRAS gain-of-function genetic cause, RAS/MAPK cascade hyperactivation as the core pathophysiology, cardiovascular disease (hypertrophic cardiomyopathy and supraventricular arrhythmias) as a major phenotype, and the characteristic malignancy predisposition. Falcon's quantified cardiac burden and the hiPSC-derived multifocal-atrial-tachycardia mechanism are strong single-provider contributions worth integrating with their primary-source citations verified.

Not integrated (leads)

Several claims are retained as leads pending further verification rather than immediate promotion. The AMPK/mitochondrial bioenergetic mechanism and the mitochondrial-modulator therapeutic hypothesis rest on a single Asta-retrieved paper (Dard 2022) with predominantly model-organism/in-vitro evidence and should be corroborated before curation. The PI3K/AKT axis is Falcon-only and the birth- prevalence estimate is Asta-only; both are plausible but single-sourced. These are held as LEAD until their underlying PMIDs/DOIs are fetched and their snippets validated in the main curation pipeline.

Cross-provider synthesis comparing falcon (Edison Scientific, a synthesized pathophysiology-focused report) and asta (a retrieval-only corpus search whose 20 hits are largely off-topic, with only a handful of genuinely Costello/RASopathy papers: Dard 2022, Kontaridis 2022, Faienza 2024, Blachowska 2016). No direct contradictions were found. Agreement centers on the HRAS gain-of-function cause and RAS/MAPK dysregulation. Divergence is complementary coverage: Falcon uniquely contributes the PI3K axis, the hiPSC atrial-cardiomyocyte MAT mechanism, and the quantified cardiac/tumor burden, while Asta uniquely surfaces the AMPK/mitochondrial bioenergetic mechanism (with mitochondrial modulators as candidate therapy) and a birth-prevalence estimate. best_matching_text values are verbatim excerpts from the cited report files.